A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2014
At a glance
- Drugs Buparlisib (Primary) ; Trametinib (Primary)
- Indications Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Pharmacogenomic
- Sponsors Novartis
- 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Nov 2014 Planned End Date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 12 Nov 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.